What is Retatrutide? A Researcher's Guide to the GLP-1/GIP/Glucagon Tri-Agonist

Retatrutide (LY3437943) is one of the most talked-about compounds in current metabolic research. As a triple receptor agonist targeting GLP-1, GIP, and glucagon receptors simultaneously, it represents a significant step forward from earlier dual-agonist compounds like Tirzepatide.

This guide covers what Retatrutide is, how it works mechanistically, and why it has attracted such significant attention in the research community.

What is Retatrutide?

Retatrutide is a synthetic peptide developed as a tri-agonist — meaning it activates three distinct receptor pathways at once. This multi-receptor approach is what distinguishes it from earlier GLP-1 mono-agonists (like Semaglutide) and dual-agonists (like Tirzepatide).

Its three targets are:

• GLP-1 receptor (GLP-1R) — involved in insulin secretion, appetite suppression, and gastric emptying
• GIP receptor (GIPR) — involved in insulin and glucagon regulation, and adipose tissue metabolism
• Glucagon receptor (GCGR) — involved in hepatic glucose production and energy expenditure

Mechanism of Action

By engaging all three receptors, Retatrutide is studied for its potential to produce complementary and additive effects across metabolic pathways. The glucagon receptor component in particular is of significant research interest — glucagon receptor agonism increases energy expenditure and promotes lipolysis, effects not seen with GLP-1 or GIP agonism alone.

This tri-receptor profile makes Retatrutide a valuable tool for researchers investigating the interplay between incretin hormones, glucagon signalling, and metabolic homeostasis.

Why Retatrutide is of Research Interest

Phase 2 clinical data published in the New England Journal of Medicine (2023) demonstrated substantial effects on body weight reduction in study participants over 48 weeks, with results exceeding those seen with earlier compounds in the same class. This has driven significant academic and commercial research interest in the tri-agonist mechanism.

Key areas of ongoing research include:

• Metabolic disease and obesity models
• Non-alcoholic steatohepatitis (NASH) and liver fat research
• Cardiovascular risk factor modulation
• Comparative receptor pharmacology studies

Retatrutide vs. Semaglutide vs. Tirzepatide

Understanding where Retatrutide sits relative to other compounds in the GLP-1 class is important for research design:

• Semaglutide — GLP-1 mono-agonist; well-characterised, extensive published data
• Tirzepatide — GLP-1/GIP dual-agonist; adds GIP receptor engagement
• Retatrutide — GLP-1/GIP/glucagon tri-agonist; adds glucagon receptor engagement for enhanced energy expenditure research

Each compound offers a distinct receptor profile, making them useful for comparative mechanistic studies.

Sourcing Retatrutide for Research

Research-grade Retatrutide should be sourced from suppliers who provide batch-specific Certificates of Analysis (CoA) confirming purity (>98%), identity, and potency. Lyophilised formats offer the best stability for laboratory storage.

At Aura Peptides, our Retatrutide is supplied as a research-grade lyophilised peptide with full CoA documentation, available as single vials or in 10x bulk packs for high-volume research programmes.

For research purposes only. Not intended for human or veterinary use.